What is Survodutide? A GLP-1/Glucagon Dual Agonist Research Overview
Survodutide (development code BI 456906) is a synthetic dual-receptor research peptide engineered to simultaneously activate the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). In the dual-receptor agonist class, survodutide occupies a different mechanistic niche from tirzepatide (GLP-1 + GIP) and from retatrutide (GLP-1 + GIP + glucagon triple agonism): survodutide pairs GLP-1 signaling with glucagon signaling, omitting the GIP arm.
This article reviews what survodutide is, what receptors it binds, what the preclinical animal-study literature reports, and how it sits in the broader incretin-research catalog. It is supplied for in vitro and animal-research use only.
Reference identifiers
- CAS Registry Number: 2384032-94-2
- Development code: BI 456906
- Sequence length: 29 amino acids
- Molecular weight: ~3618 g/mol
- Form supplied: Lyophilized white powder
- Originator: Boehringer Ingelheim / Zealand Pharma
The CoA should report HPLC purity ≥99.0% with chromatogram visible, mass spectrum confirmation within ±0.5 Da of theoretical, net peptide content, and lot number matching the vial. Any reputable research-supply vendor should publish the CoA per lot; verify that the lot number on the vial resolves to a downloadable PDF before use.
Dual receptor pharmacology
Survodutide is engineered for balanced agonism at GLP-1R and GCGR. The published characterization indicates the peptide engages both receptors at nanomolar potency, with a designed activity ratio between the two receptors that distinguishes survodutide pharmacologically from compounds optimized primarily for GLP-1 activity with weak glucagon-receptor cross-reactivity [Zimmermann T et al., 2022, Cell Reports Medicine, DOI 10.1016/j.xcrm.2022.100735].
GLP-1R component
The GLP-1R component of survodutide produces the canonical incretin response: glucose-dependent insulin secretion, suppression of α-cell glucagon release, delayed gastric emptying, and central satiety signaling. These effects are well-characterized and overlap with the activity of GLP-1R monoagonists like semaglutide and liraglutide.
Glucagon receptor component
The glucagon-receptor component is the mechanistically distinctive feature. Glucagon, the canonical α-cell hormone, signals through the hepatic glucagon receptor to increase glycogenolysis and gluconeogenesis — the “raise blood glucose” arm of glucose homeostasis. Why would a metabolic research compound activate the receptor that raises glucose?
The answer is that glucagon signaling has metabolic effects beyond hepatic glucose output. In animal studies, glucagon-receptor activation has been associated with:
– Increased basal metabolic rate and energy expenditure
– Modulation of hepatic lipid metabolism and triglyceride clearance
– Stimulation of brown adipose tissue thermogenesis in rodent models
– Effects on bile acid metabolism
When paired with GLP-1R activation — which produces glucose-dependent insulin secretion and suppresses α-cell glucagon — the net effect on glucose homeostasis is modulated rather than dominated by either signal alone. The result, in preclinical models, is a metabolic profile distinct from GLP-1 monoagonists: comparable weight reduction with additional energy-expenditure and hepatic-lipid effects.
Preclinical animal-study findings
The published animal-study literature for survodutide reports:
– Dose-dependent reductions in food intake and body weight in DIO mouse and rat models
– Improved glucose tolerance under sustained dosing
– Reductions in hepatic triglyceride content and improvements in histological steatosis scoring in animal models of metabolic-dysfunction-associated steatotic liver disease (MASLD/MASH)
– Increased markers of energy expenditure relative to GLP-1R monoagonist comparators
The MASLD/MASH preclinical findings reflect the broader research interest in glucagon-receptor-engaging compounds for hepatic lipid biology. The 2024 Phase 2 clinical results in MASH/MASLD have been published in the peer-reviewed literature [Sanyal AJ et al., 2024, NEJM, DOI 10.1056/NEJMoa2401755]; researchers conducting preclinical work in liver-disease models may find the human comparator context useful for experimental design.
These findings are reported in research context only. None of them constitute evidence of safety or efficacy in humans.
How survodutide fits in the dual/triple agonist class
The incretin-axis research peptide catalog now includes:
| Compound | Receptors engaged |
|---|---|
| Semaglutide, liraglutide | GLP-1R only |
| Tirzepatide | GLP-1R + GIPR |
| Survodutide | GLP-1R + GCGR |
| Retatrutide | GLP-1R + GIPR + GCGR |
| Mazdutide | GLP-1R + GCGR (alternative dual agonist) |
For broader comparison context, see the tirzepatide mechanism deep-dive.
CoA verification
Standard CoA points for survodutide:
– HPLC purity ≥99.0% with chromatogram visible
– Mass spectrum confirming expected [M+H]⁺ within ±0.5 Da
– Sequence confirmation — the 29-residue engineered backbone with the specific fatty-acid modification should be documented
– Net peptide content with counterion identified
– Lot number matching vial
Storage
Survodutide is supplied lyophilized. Pre-reconstitution: 2–8°C, dry, dark; -20°C for archival storage. Post-reconstitution: 2–8°C in multi-dose diluent, use within ~28 days. Reconstitute by adding diluent slowly to vial wall; no shaking.
Summary
Survodutide is a 29-amino-acid GLP-1/glucagon dual-receptor agonist research peptide with a balanced agonism profile at both target receptors. In preclinical animal-study models it has been reported to reduce body weight, improve glucose tolerance, and modulate hepatic lipid metabolism, with energy-expenditure effects attributed to the glucagon-receptor arm. It fills a specific niche in the incretin-research catalog — the GLP-1 + glucagon dual-agonist research probe — distinct from the GLP-1 + GIP class (tirzepatide) and the triple-receptor class (retatrutide).
Research Use Only. Not for use in or on humans or animals. Not a food, drug, cosmetic, or supplement.